Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children

CONCLUSIONS: Nirsevimab demonstrated clinical efficacy in reducing RSV-associated MA-LRTI and RSV-associated hospitalizations in infants and was well tolerated.PMID:38654469 | DOI:10.1177/10600280241243357

Source: The Annals of Pharmacotherapy - April 24, 2024 Category: Drugs & Pharmacology Authors: J Hunter Fly Lea S Eiland Jeremy S Stultz Source Type: research